Partnering opportunity

Highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics, based on proprietary epigenetic biomarkers

Summary

A young German SME specialized in molecular biology and cancer diagnostics has developed a fast molecular diagnostic MDx test based on epigenetic changes (DNA methylation) which are characteristic for cancer cells. These highly informative biomarkers validated in clinical trials and applicable for early detection of cervical cancer. Corresponding marker sets for head-and-neck tumor and ovarian cancer are also validated. Seeking medical partners for licensing and technical cooperation agreements.

Partner sought

Medical partners sought for License and Technical cooperation agreements: The company is looking for exclusive diagnostic providers in the cancer area especially in the US and Europe with corresponding technical background and capabilities for market promotion. • HPV-testing providers • Liquid-Based-Cytology (LBC) companies • MDx Platform Providers • MDx Marketing and Distribution Companies • MDx Development Companies For the head-and-neck and ovarian cancer pipeline projects, the company is interested in joint technology development partners.

Description

Cervical cancer is the third most common cancer in women world-wide, with approx. 530,000 new cases and 275,000 deaths per year. In contrast to other cancers it mainly affects young women with a maximum of incidence below 30 years of age. Current screening programs have reduced mortality over the past 40 years. However, they require further improvements because up to 50% of all precancerous lesions or cancers are overlooked, while too many surgeries are performed. Unnecessary surgeries increase the risk for preterm birth (factor 2-4) and perinatal death risk by a factor of 10 in post-surgery pregnancies and put high cost burden on all players in the health economy system. As a consequence, the medical need is twofold: introduction of effective screening systems in less developed regions and reduction of over-therapy in more developed regions. In the area of head-and-neck and ovarian cancer, the company’s marker panels may support post-surgical treatment decisions and may thus also be implemented as companion diagnostics for chemotherapy treatment decisions. This is especially important as in up to 65% of all cases, these types of tumours frequently relapse (recidivation) following surgical removal because the patient is resistant to platin-containing chemotherapy substrates. Reliable triage testing of positive screening patients is important to reduce their psychological burden in ongoing watchful-waiting and retesting periods. Triage testing of positive screening results by the company’s MDx test therefore decreases psychologic stress evoked by false-positive diagnoses. This is especially important for women still in family planning, because invasive diagnostics and esp. surgery increases the risk for preterm birth and perinatal death. The company has already licensed out the test for the Chinese market to a major medical player in China, including all relevant tech transfer documents. Following this market entry in China, the company is open to discuss commercialization of the test in all other regions, especially Europe and the US. Potential partners may derive from diagnostics companies which are already active in the HPV-testing segment, and/or which are seeking expansion for their own MDx platforms. Pharmaceutical companies focused on women's health segments are also potential partners, preferring licensing and technical cooperation agreements. The company is looking for exclusive diagnostic providers in the cancer area especially in the US and Europe with corresponding technical background and capabilities for market promotion. • HPV-testing providers • Liquid-Based-Cytology (LBC) companies • MDx Platform Providers • MDx Marketing and Distribution Companies and MDx Development Companies For the head-and-neck and ovarian cancer pipeline projects, the company is interested in joint technology development partners.

Advantages and innovations

Proprietary epigenetic markers, developed by the company in connection with a reknown university hospital since 2008, have various advantages: • They are specifically linked to carcinogenesis of tumor cells – contrary to the current screening tests which are, in the case of cervical cancer, linked to HPV infection • They detect stable and robust DNA cell regulation mechanisms • Easy to use & objective read-out: Markers detected with established PCR-based technology • Fast turn-around: Time to result < 6 h, hands-on time < 2h • Robust & economic: No specific requirements for the material used in the test Established screening programs in cervical cancer based on liquid-based cytology (LBC) samples have prepared the market for innovative triage tests. Such LBC samples allow different tests from one cervical smear sample: cytology, HPV, and other biomarkers. The CE-IVD cervical cancer test of the company is the ideal triage test in this setting because it • detects all cancer cases • has good sensitivity for the relevant precancerous stage CIN3 (i.e. detects the relevant CIN3 which may progress to cancer) - prognostic value as USP • has excellent specificity with normal cytology The corresponding market potential is more than €1 billion per year. It offers and includes a significant upside from advances in implementation of HPV testing in primary cervical cancer screening. Expansion with a lower-end market price product to emerging countries offers additional upsides. The company is working on proof-of-concept studies for implementation of relevant biomarkers into point-of-care diagnostic tests.

Development stage

Already on the market

Intellectual Property Rights (IPR)

Secret Know-how,Patents granted,Trade Marks


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company